Tan, Xi
Divino, Victoria
Amamoo, James
Xie, Lin
Coyle, Katharine B.
Gamble, Cory L.
Guevarra, Mico
Paprocki, Yurek
King, Aaron A.
Funding for this research was provided by:
Novo Nordisk Inc
Article History
Accepted: 28 February 2024
First Online: 20 March 2024
Declarations
:
: This study was funded by Novo Nordisk Inc.
: XT, JA, LX, CLG, MG, YP are employed by Novo Nordisk Inc. LX has been employed by Pfizer within the last 3 years. VD and KBC are employees of IQVIA, which received funding from Novo Nordisk Inc. for this study. AK is an employee of Baptist Medical Network MedFirst Primary Care – Quarry, and served as consultant/speaker for Abbott, Astellas, Dexcom, Eli Lilly, Mannkind, and Novo Nordisk Inc.
: The original de-identified data used in this analysis were obtained from and are the property of IQVIA. IQVIA has restrictions prohibiting the authors from making the data set publicly available. Interested researchers may contact IQVIA to apply to gain access to the study’s data in the same way the authors obtained the data (see ExternalRef removed).
: Researchers accessed data in compliance with the Health Insurance Portability and Accountability Act (HIPAA). This study was considered exempt from the requirements for research in human subjects in the US because it was a retrospective analysis of commercially available, de-identified secondary data.
: Not applicable.
: Not applicable.
: All authors were involved in the concept and design of the study, data interpretation, as well as critically reviewing, editing, and approving the manuscript. VD and KBC were also involved in data analyses.